All In Biotech

Drug Trial Radar · NCT00912964

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder

Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,030 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,030

Actual

Start

Apr 28, 2009

Primary completion

Apr 27, 2010

Study completion Apr 27, 2010

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jun 3, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.

Conditions

  • Urinary Bladder, Overactive

Interventions

  • MirabegronDrug

    Mirabegron tablets

  • PlaceboDrug

    Matching mirabegron placebo tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and Week 12
  2. Change From Baseline to End of Treatment (Final Visit) in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and Week 12

Locations

151 sites in 11 countries. Site status is shown where the registry gives one.

  • Site not named

    Homewood, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Atherton, California

  • Site not named

    Buena Park, California

  • Site not named

    Fresno, California

  • Site not named

    La Mesa, California

  • Site not named

    Los Angeles, California

  • Site not named

    Newport Beach, California

  • Site not named

    San Bernardino, California

  • Site not named

    San Diego, California

  • Site not named

    Tarzana, California

  • Site not named

    Torrance, California

  • Site not named

    Denver, Colorado

  • Site not named

    New Britain, Connecticut

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Aventura, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Lauderdale Lakes, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tallahassee, Florida

  • Site not named

    Wellington, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Alpharetta, Georgia

  • Site not named

    Roswell, Georgia

  • Site not named

    Melrose Park, Illinois

  • Site not named

    Fort Wayne, Indiana

  • Site not named

    Jeffersonville, Indiana

  • Site not named

    West Des Moines, Iowa

  • Site not named

    Overland Park, Kansas

  • Site not named

    Wichita, Kansas

Showing 40 of 151 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.